USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: STEMINA BIOMARKER DISCOVERY, INC.
City: MADISON
State: WI
Zip+4: 53719-1256
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (608) 204-0104

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $445,449.00 3
SBIR Phase II $1,499,936.00 2

Award List:

SBIR TOPIC 245 "PREDICTIVE EFFICACY SCREENING IN CANCER STEM CELLS USING METABOLO

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul West
Award Amount: $149,528.00
Abstract:
Cancer stem cells (CSCs) are a critical tumor subpopulation that may cause local recurrences that plague patients with advanced solid malignancies, even after maximal therapeutic efforts. CSCs can self-renew, differentiate into multiple lineages, resist ra diation and chemotherapy, and efficiently… More

SBIR Phase I: Metabolomics of Human Embryonic Stem Cells to Predict Teratogenicity: An Alternative Developmental Toxicity Model

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: NSF
Principal Investigator: Paul R. West, PhD
Award Amount: $149,255.00
Abstract:
This Small Business Innovation Research (SBIR) Phase I project proposes to develop a highly predictive model for assessing the potential of compounds to cause birth defects in the developing human embryo using human embryonic stem (hES) cells as the test substrate. The project proposes to use hES… More

Not Available

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Paul West
Award Amount: $999,936.00
Abstract:
Brain tumor stem cells (BTSCs) are a subset population within tumors that are widely believed to be  responsible for tumor recurrence, due to their ability to self-renew, differentiate, migrate, and initiate tumor  propagation. Given these unique features, the selective targeting of BTSCs… More

SBIR Phase II: Metabolomics of Human Embryonic Stem Cells to Predict Teratogenicity: An Alternative Developmental Toxicity Model

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: NSF
Principal Investigator: Paul R. West
Award Amount: $500,000.00
Abstract:
This Small Business Innovation Research (SBIR) Phase II project will fund a continuation of breakthrough research, development and commercialization of an in vitro assay to help prevent birth defects. This innovative product is driven by a need to create a test for human developmental toxicity that… More

Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Plurip

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert E. Burrier – 608-204-0104
Award Amount: $146,666.00
Abstract:
DESCRIPTION (provided by applicant): Cardiotoxicity, as a result of adverse drug effects, is a serious problem that has yet to be effectively screened prior to patient exposure. Cardiac safety is one of the leading causes of compound attrition in the pharmaceutical industry and withdrawal of… More